BlackRock’s Lyell Immunopharma LYEL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.28M | Sell |
144,859
-491,220
| -77% | -$4.34M | ﹤0.01% | 4104 |
|
|
2025
Q1 | $6.84M | Sell |
636,079
-27,214
| -4% | -$293K | ﹤0.01% | 3462 |
|
|
2024
Q4 | $8.49M | Sell |
663,293
-24,061
| -4% | -$308K | ﹤0.01% | 3464 |
|
|
2024
Q3 | $19M | Buy |
687,354
+12,597
| +2% | +$348K | ﹤0.01% | 3039 |
|
|
2024
Q2 | $19.6M | Sell |
674,757
-19,874
| -3% | -$576K | ﹤0.01% | 2955 |
|
|
2024
Q1 | $31M | Sell |
694,631
-20,480
| -3% | -$913K | ﹤0.01% | 2683 |
|
|
2023
Q4 | $27.7M | Buy |
715,111
+44,099
| +7% | +$1.71M | ﹤0.01% | 2768 |
|
|
2023
Q3 | $19.7M | Buy |
671,012
+16,922
| +3% | +$498K | ﹤0.01% | 2902 |
|
|
2023
Q2 | $41.6M | Buy |
654,090
+37,233
| +6% | +$2.37M | ﹤0.01% | 2551 |
|
|
2023
Q1 | $29.1M | Buy |
616,857
+8,406
| +1% | +$397K | ﹤0.01% | 2726 |
|
|
2022
Q4 | $42.2M | Buy |
608,451
+22,096
| +4% | +$1.53M | ﹤0.01% | 2549 |
|
|
2022
Q3 | $86M | Buy |
586,355
+86,369
| +17% | +$12.7M | ﹤0.01% | 2048 |
|
|
2022
Q2 | $65.2M | Buy |
499,986
+109,511
| +28% | +$14.3M | ﹤0.01% | 2283 |
|
|
2022
Q1 | $39.4M | Buy |
390,475
+290,502
| +291% | +$29.3M | ﹤0.01% | 2675 |
|
|
2021
Q4 | $15.5M | Buy |
99,973
+28,628
| +40% | +$4.43M | ﹤0.01% | 3363 |
|
|
2021
Q3 | $21.1M | Buy |
71,345
+58,965
| +476% | +$17.5M | ﹤0.01% | 3190 |
|
|
2021
Q2 | $4.02M | Buy |
+12,380
| New | +$4.02M | ﹤0.01% | 3905 |
|